Crizotinib - Pfizer

Drug Profile

Crizotinib - Pfizer

Alternative Names: PF-002341066; PF-02341066; PF-1066; PF-2341066; Xalkori

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Dana-Farber Cancer Institute; National Cancer Institute (USA); OxOnc Development; Pfizer; University of Colorado at Denver; University of Milan Bicocca
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Piperidines; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto oncogene protein c met inhibitors; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Bladder cancer; Non-Hodgkin's lymphoma; Renal cell carcinoma
  • Phase I Glioblastoma; Prostate cancer; Solid tumours

Most Recent Events

  • 22 Mar 2018 Pfizer terminates a phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA due to a decision based on the low enrolment (IV) (NCT02511184)
  • 13 Dec 2017 Phase-II clinical trials in Non-small cell lung cancer (Neoadjuvant therapy, Late-stage disease) in USA (PO) (NCT03088930)
  • 09 Dec 2017 Adverse events and efficacy data from a phase Ib trial in Solid tumours presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top